Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model | Zendy

Arnold Louie | Zendy; Brandon Duncanson | Zendy; Jenny Myrick | Zendy; Michael S. Maynard | Zendy; Jocelyn Nole | Zendy; David Brown | Zendy; Stephan Schmidt | Zendy; Michael Neely | Zendy; Charles A. Scanga | Zendy; Charles A. Peloquin | Zendy; George L. Drusano | Zendy

Open Access

Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model

Author(s) -

Arnold Louie,

Brandon Duncanson,

Jenny Myrick,

Michael S. Maynard,

Jocelyn Nole,

David Brown,

Stephan Schmidt,

Michael Neely,

Charles A. Scanga,

Charles A. Peloquin,

George L. Drusano

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01470-18

Subject(s) - moxifloxacin , mycobacterium tuberculosis , bedaquiline , tuberculosis , microbiology and biotechnology , antibiotics , multidrug tolerance , drug resistance , medicine , phase (matter) , biology , bacteria , chemistry , genetics , biofilm , pathology , organic chemistry

A major goal for improving tuberculosis therapy is to identify drug regimens with improved efficacy and shorter treatment durations. Shorter therapies improve patient adherence to the antibiotic regimens, which, in turn, decreases resistance emergence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research